Xanthan gum as an adjuvant in a subunit vaccine preparation against leptospirosis

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Bacelo, Katia L ^a   Hartwig, Daiane D ^a   Seixas, Fabiana K ^a   Schuch, Rodrigo ^a   Moreira, Angelita Da S ^a   Amaral, Marta ^a   Collares, Tiago ^a   Vendrusculo, Claire T ^a   McBride, Alan J A ^a   Dellagostin, Odir A ^a  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CPG OLIGODEOXYNUCLEOTIDE; LEPTOSPIROSIS VACCINE; SUBUNIT VACCINE; XANTHAN; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; IMMUNOLOGICAL ADJUVANT; NITROGEN; PYRUVIC ACID;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGENICITY; ARTICLE; BACTERIAL STRAIN; CHINESE; CHO CELL LINE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; LEPTOSPIRA INTERROGANS; LEPTOSPIROSIS; MOLECULAR WEIGHT; NONHUMAN; SYRIAN HAMSTER; XANTHOMONAS; ANIMAL; ANTIBODY PRODUCTION; CELL DEATH; CRICETULUS; DISEASE MODEL; DRUG EFFECTS; HAMSTER; HUMIDITY; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGY; MESOCRICETUS; MICROBIOLOGY; PHYSIOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACTERIAL VACCINES; CELL DEATH; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; FEMALE; HUMIDITY; IMMUNITY, HUMORAL; IMMUNIZATION; LEPTOSPIRA INTERROGANS; LEPTOSPIROSIS; MESOCRICETUS; NITROGEN; POLYSACCHARIDES, BACTERIAL; PYRUVIC ACID; VACCINES, SUBUNIT;

EID: 84901802115     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/636491     Document Type: Article

References (36)

1. WHO, Human Leptospirosis: Guidance for Diagnosis Survillance and Control 2003 Geneve, Switzerland WHO Library Cataloguing-in-Publication Data
2. Levett P. N., Leptospirosis. Clinical Microbiology Reviews 2001 14 2 296 326 2-s2.0-0035072803 10.1128/CMR.14.2.296-326.2001 (Pubitemid 32294672)
3. Burnette W. N., Recombinant subunit vaccines. Current Opinion in Biotechnology 1991 2 6 882 892 2-s2.0-0026288628
4. Odir A. D., Grassmann A. A., Hartwig D. D., Félix S. R., da Silva É. F., McBride A. J. A., Recombinant vaccines against leptospirosis. Human Vaccines 2011 7 11 1215 1224 2-s2.0-81855183700
5. Coutinho M. L., Choy H. A., Kelley M. M., Matsunaga J., Babbitt J. T., Lewis M. S., Aleixo J. A. G., Haake D. A., A ligA three-domain region protects hamsters from lethal infection by leptospira interrogans. PLoS Neglected Tropical Diseases 2011 5 12 2-s2.0-84855265972 10.1371/journal.pntd.0001422 e1422
6. Lucas D. S. D., Cullen P. A., Lo M., Srikram A., Sermswan R. W., Adler B., Recombinant LipL32 and LigA from Leptospira are unable to stimulate protective immunity against leptospirosis in the hamster model. Vaccine 2011 29 18 3413 3418 2-s2.0-79954680218 10.1016/j.vaccine.2011.02.084
7. Forster K. M., Hartwig D. D., Seixas F. K., A conserved region of leptospiral immunoglobulin-like A and B proteins as a DNA vaccine elicits a prophylactic immune response against leptospirosis. Clinical and Vaccine Immunoogy 2013 20 5 725 731 10.1128/CVI.00601-12
8. Clements C. J., Griffiths E., The global impact of vaccines containing aluminium adjuvants. Vaccine 2002 20 supplement 3 S24 S33 2-s2.0-0037205084 (Pubitemid 34607672)
9. Baylor N. W., Egan W., Richman P., Aluminum salts in vaccines-US perspective. Vaccine 2002 20 supplement 3 S18 S23 2-s2.0-0037205207 10.1016/S0264-410X(02)00166-4 (Pubitemid 34607671)
10. Sutherland I. W., Novel and established applications of microbial polysaccharides. Trends in Biotechnology 1998 16 1 41 46 2-s2.0-0031909010 10.1016/S0167-7799(97)01139-6 (Pubitemid 28064817)
11. Mohd Sauid S., Krishnan J., Ling T. H., Veluri M. V., Enhancement of oxygen mass transfer and gas holdup using palm oil in stirred tank bioreactors with Xanthan solutions as simulated viscous fermentation broths. BioMed Research International 2013 2013 9 409675 10.1155/2013/409675
12. Chiou C.-J., Tseng L.-P., Deng M.-C., Jiang P.-R., Tasi S.-L., Chung T.-W., Huang Y.-Y., Liu D.-Z., Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens. Biomaterials 2009 30 29 5862 5868 2-s2.0-68549088703 10.1016/j.biomaterials.2009.06.046
13. Takeuchi A., Kamiryou Y., Yamada H., Eto M., Shibata K., Haruna K., Naito S., Yoshikai Y., Oral administration of xanthan gum enhances antitumor activity through Toll-like receptor 4. International Immunopharmacology 2009 9 13-14 1562 1567 2-s2.0-70350564316 10.1016/j.intimp.2009.09.012
14. Ishizaka S., Sugawara I., Hasuma T., Immune responses to xanthan gum. I. The characteristics of lymphocyte activation by xanthan gum. European Journal of Immunology 1983 13 3 225 231 2-s2.0-0020528361 (Pubitemid 13112744)
15. Bertram U., Bernard M.-C., Haensler J., Maincent P., Bodmeier R., In situ gelling nasal inserts for influenza vaccine delivery. Drug Development and Industrial Pharmacy 2010 36 5 581 593 2-s2.0-77952607745 10.3109/ 03639040903382673
16. Vendruscolo C. T., Vedruscolo J. L. S., Moreira A. S., Process for Preparing a Xanthan Biopolymer 2005 Universidade Federal de Pelotas, Empresa Brasileira de Pesquisa Agropecuária WO/2006/047845
17. Burdock G., Encyclopedia of Food and Color Additives 1997 3rd New York, NY, USA CRC Press
18. FAO/WHO, Compendium of food additive specifications. Addendum 7. Proceedings of the Joint FAO/WHO Expert Committee on Food Additives 53rd Session June 1999
19. Moreira A. S., Vendruscolo J. L. S., Gil-Turnes C., Vendruscolo C. T., Screening among 18 novel strains of Xanthomonas campestris pv pruni. Food Hydrocolloids 2001 15 4-6 469 474 2-s2.0-0035176929 10.1016/S0268-005X(01)00092- 3 (Pubitemid 33086074)
20. Silva É. F., Medeiros M. A., McBride A. J. A., Matsunaga J., Esteves G. S., Ramos J. G. R., Santos C. S., Croda J., Homma A., Dellagostin O. A., Haake D. A., Reis M. G., Ko A. I., The terminal portion of leptospiral immunoglobulin-like protein LigA confers protective immunity against lethal infection in the hamster model of leptospirosis. Vaccine 2007 25 33 6277 6286 2-s2.0-34447630469 10.1016/j.vaccine.2007.05.053 (Pubitemid 47088033)
21. Félix S. R., Hartwig D. D., Argondizzo A. P. C., Silva É. F., Seixas F. K., Neto A. C. P. S., Medeiros M. A., Lilenbaum W., Dellagostin O. A., Subunit approach to evaluation of the immune protective potential of leptospiral antigens. Clinical and Vaccine Immunology 2011 18 12 2026 2030 2-s2.0-83455259664 10.1128/CVI.05297-11
22. Weeratna R., Comanita L., Davis H. L., CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice. Immunology and Cell Biology 2003 81 1 59 62 2-s2.0-0037324369 10.1046/j.1440-1711.2003.01135.x (Pubitemid 36237793)
23. Seixas F. K., da Silva É. F., Hartwig D. D., Cerqueira G. M., Amaral M., Fagundes M. Q., Dossa R. G., Dellagostin O. A., Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 2007 26 1 88 95 2-s2.0-36749036783 10.1016/j.vaccine.2007.10.052 (Pubitemid 350213201)
24. Hartwig D. D., Bacelo K. L., Oliveira P. D., Mannosylated LigANI produced in Pichia pastoris protects hamsters against leptospirosis. Current Microbiology 2014 68 4 524 530 10.1007/s00284-013-0505-4
25. Pasare C., Medzhitov R., Toll-dependent control mechanisms of CD4 T cell activation. Immunity 2004 21 5 733 741 2-s2.0-8444245925 10.1016/j.immuni.2004. 10.006 (Pubitemid 39487894)
26. Pasare C., Medzhitov R., Control of B-cell responses by Toll-like receptors. Nature 2005 438 7066 364 368 2-s2.0-27844541797 10.1038/nature04267 (Pubitemid 41643953)
27. Vendruscolo C. T., Moreira A. S., Souza A. S., Zambiazi R., Scamparini A. R. P., Nishinari K., Heteropolysaccharides produced by Xanthomonas campestris pv pruni C24. Hydrocolloids 2000 Japan Elsevier 187 191
28. Dow J. M., Osbourn A. E., Wilson T. J., Daniels M. J., A locus determining pathogenicity of Xanthyomonas campestris is involved in lipopolysaccharide biosynthesis. Molecular Plant-Microbe Interactions 1995 8 5 768 777 2-s2.0-0029377645 (Pubitemid 3002120)
29. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D. M., CpG DNA as a vaccine adjuvant. Expert Review of Vaccines 2011 10 4 499 511 2-s2.0-79955124819 10.1586/erv.10.174
30. Gursel I., Gursel M., Ishii K. J., Klinman D. M., Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. Journal of Immunology 2001 167 6 3324 3328 2-s2.0-0035885126 (Pubitemid 32852574)
31. Klinman D. M., Immunotherapeutic uses of CpG oligodeoxynucleotides. Nature Reviews Immunology 2004 4 4 249 258 2-s2.0-1842631153 (Pubitemid 38478660)
32. Rankin R., Pontarollo R., Gomis S., Karvonen B., Willson P., Loehr B. I., Godson D. L., Babiuk L. A., Hecker R., Van Drunen Littel-Van Den Hurk S., CpG-containing oligodeoxynucleotides augment and switch the immune responses of cattle to bovine herpesvirus-1 glycoprotein D. Vaccine 2002 20 23-24 3014 3022 2-s2.0-0037178315 10.1016/S0264-410X(02)00216-5 (Pubitemid 34785973)
33. Faisal S. M., Yan W., McDonough S. P., Chang Y.-F., Leptospira immunoglobulin-like protein A variable region (LigAvar) incorporated in liposomes and PLGA microspheres produces a robust immune response correlating to protective immunity. Vaccine 2009 27 3 378 387 2-s2.0-57649213862 10.1016/j.vaccine.2008.10.089
34. Palaniappan R. U. M., McDonough S. P., Divers T. J., Chen C.-S., Pan M.-J., Matsumoto M., Chang Y.-F., Immunoprotection of recombinant leptospiral immunoglobulin-like protein A against Leptospira interrogans serovar pomona infection. Infection and Immunity 2006 74 3 1745 1750 2-s2.0-33644753762 10.1128/IAI.74.3.1745-1750.2006 (Pubitemid 43346809)
35. Dyondi D., Webster T. J., Banerjee R., A nanoparticulate injectable hydrogel as a tissue engineering scaffold for multiple growth factor delivery for bone regeneration. International Journal of Nanomedicine 2013 8 47 59
36. Chellat F., Tabrizian M., Dumitriu S., In vitro and in vivo biocompatibility of chitosan-xanthan polyionic complex. Journal of Biomedical Materials Research 2000 51 1 107 116 (Pubitemid 30331988)